Woodline Partners’s Crinetics Pharmaceuticals CRNX Stock Holding History

Woodline Partners’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.23M	Hold	32,817	–	–	﹤0.01%	893
2026 Q1	$1.19M	Buy	+32,817	New	+$1.47M	﹤0.01%	861
2025 Q1	–	Sell	-50,000	Closed	-$2.56M	–	926
2024 Q4	$2.56M	Buy	+50,000	New	+$2.8M	0.02%	616
2024 Q2	–	Sell	-153,395	Closed	-$7.18M	–	581
2024 Q1	$7.18M	Buy	153,395 +3,395	+2%	+$133K	0.07%	318
2023 Q4	$5.34M	Hold	150,000	–	–	0.06%	312
2023 Q3	$4.46M	Buy	+150,000	New	+$3.09M	0.05%	326

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Woodline Partners's CRNX Position: Q2 2026 in Review

Woodline Partners held its Crinetics Pharmaceuticals (CRNX) position steady in Q2 2026 at 32,817 shares worth $1.23M. The position accounts for ﹤0.01% of the portfolio, ranked #893.

Woodline Partners first reported a position in CRNX in Q3 2023 and has held it in 6 quarters since. The position peaked at $7.18M in Q1 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Woodline Partners held 32,817 shares of Crinetics Pharmaceuticals worth $1.23M as of Q2 2026.
Woodline Partners left its Crinetics Pharmaceuticals share count unchanged in Q2 2026.
Crinetics Pharmaceuticals made up ﹤0.01% of Woodline Partners's portfolio in Q2 2026, its #893 holding.
Woodline Partners first reported a position in Crinetics Pharmaceuticals in Q3 2023 and has held it in 6 quarters since.
Woodline Partners's Crinetics Pharmaceuticals position peaked at $7.18M in Q1 2024.
267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.